ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0711

Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies

Sangmee Bae1, Ani Shahbazian2, Jennifer Wang2 and Christina Charles-Schoeman2, 1University of California Los Angeles, Los Angeles, CA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2021

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with idiopathic inflammatory myopathies have accelerated vascular disease, which contributes to higher disease morbidity and mortality. Apolipoprotein A-I (apoA-I) is the major protein component of HDL, which suppresses vascular inflammatory responses through promotion of cholesterol efflux and prevention of low density lipoprotein (LDL) oxidation. The current work assessed HDL-associated ApoA-I levels (HDL-apoA-I) in IIM patients compared to healthy controls, and evaluated associations of HDL-apoA-I with specific IIM disease characteristics.

Methods: HDL-apoA-I levels were measured by sandwich ELISA using a primary HDL antibody. HDL-apoA-I levels, demographic variables and traditional cardiovascular risk factors were compared in 122 IIM patients and 110 healthy controls (HC). HDL-apoA-I levels were also assessed separately in a large IIM extended patient cohort (n=274) in relation to clinical and laboratory IIM disease characteristics. Multivariate linear regression analyses were performed to further assess predictors associated with HDL-apoA-I while adjusting for statistically significant univariate variables.

Results: HDL-apoA-I levels were significantly lower in IIM patients compared to HC (Table 1). The association between low HDL-apoA-I and IIM diagnosis remained strong after multivariate adjustment (Table 2). In linear regression analysis of the extended IIM patient group (Table 3), higher MD global disease activity scores by visual analog and likert scales as well as the presence of dermatomyositis (vs polymyositis or inclusion body myositis) and the presence of certain myositis specific autoantibodies (ab) (MDA5 and TIF1< ![if !msEquation] >< ![if !vml] >< ![endif] >< ![endif] > ab) were associated with lower HLD-apoA-I levels. In multivariate analysis, the presence of MDA5 or TIF1γ ab remained significantly associated with lower HDL-apoA-I levels (regression coefficient β= -1.35, p< 0.001 and β= -0.81, p=0.01 respectively).

Conclusion: HDL-apoA-I levels were significantly lower in IIM patients compared to HC, and inversely associated with the presence of MDA5 and TIF1γ ab. Our results indicate a potential mechanism for the microvascular inflammation and damage in IIM, particularly in patients with MDA5 and TIF1γ ab.

Table 1. Clinical and laboratory characteristics of IIM patients and controls
Values are mean±SD or N(%) unless specified
*P<0.05, **P<0.0001 by student’s t test and Wilcoxon rank sum test
‡Defined as first degree relative with MI at age <55 for male and <65 for female
Abbreviations: MI, myocardial infarction; TIA, transient ischemic attack; BMI, body mass index; FHx, family history; hsCRP, high sensitivity C-reactive protein

Table 2. Multivariate Regression Analysis of Variables associated with HDL-apoA-I† activity in IIM patients and Healthy Controls (n=232)
†Log transformation was used for skewed variables (apoA-I, hsCRP)

Table 3. Univariate Linear regression Analysis of variables associated with HDL-apoA-I† levels in Patients with IIM including IIM disease specific variables (n=274)
Values are mean±SD or N(%) unless specified
*p<0.05
† Log transformation was used for skewed variables to fit linearity assumption, apoA-I, CK, ESR, hsCRP
Abbreviations: MI, myocardial infarction; TIA, transient ischemic attack; BMI, body mass index; FHx, family history; VAS, visual analog scale; HAQ, health assessment questionnaire


Disclosures: S. Bae, None; A. Shahbazian, None; J. Wang, None; C. Charles-Schoeman, AbbVie, 2, 5, Bristol-Myers Squibb, 5, Pfizer Inc, 2, 5, Gilead Sciences, 2, Sanofi-Regeneron, 2.

To cite this abstract in AMA style:

Bae S, Shahbazian A, Wang J, Charles-Schoeman C. Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/suppression-of-hdl-associated-apolipoprotein-a-i-apoa-i-levels-in-patients-with-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suppression-of-hdl-associated-apolipoprotein-a-i-apoa-i-levels-in-patients-with-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology